SCHEMBL6350221

SCHEMBL6350221

O=C(O)CC1CC(=O)c2ccccc2O1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.55
ADORA3 P0DMS8 3/20 0.55
AR P10275 2/20 0.55
KDM4E B2RXH2 1/20 0.55
CYP19A1 P11511 1/20 0.55
HSD17B10 Q99714 1/20 0.55
SIGMAR1 Q99720 4/20 0.54
ABCB1 P08183 3/20 0.54
HTR1A P08908 1/20 0.51
NPC1 O15118 2/20 0.49
MAPT P10636 2/20 0.49
RAB9A P51151 2/20 0.49
HSD11B1 P28845 1/20 0.49
AKR1C3 P42330 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPK1 P28482 1/20 0.49
AXL P30530 1/20 0.46
HTT P42858 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6746035 0.82 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL30997908 0.82 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL6745976 0.80 ABCB1 (0.49) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL68082 0.80 AR (0.51) ARCYP19A1HSD17B10SIGMAR1ABCB1
SCHEMBL9425471 0.80 MAOB (0.44) MAOBARCYP19A1ABCB1
SCHEMBL90825 0.80 AR (0.51) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL11377847 0.79 SIGMAR1 (0.66) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL8596185 0.79 MAOB (0.53) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL8873822 0.79 MAOB (0.53) MAOBADORA3ARKDM4ECYP19A1
SCHEMBL23662356 0.79 MAOB (0.56) MAOBADORA3ARKDM4ECYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903227-B2 Synthesis of 2-acyl substituted chromanes and intermediates thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-06-07 US disclosed
US-20030233002-A1 Synthesis of 2-Acyl substituted chromanes and intermediates thereof MILLENNIUM PHARMACEUTICALS, INC. 2003-12-18 US disclosed
WO-2001092250-A2 SYNTHESIS OF 2-ACYL SUBSTITUTED CHROMANES AND INTERMEDIATES THEREOF COR THERAPEUTICS, INC. (US) 2001-12-06 WO disclosed
US-5326784-A Psychological and gastrointestinal disorders INSTITUT DE RECHERCHE JOUVEINAL (FR) 1994-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030233002-A1 Synthesis of 2-Acyl substituted chromanes and intermediates thereof PLA2G7, PAFAH1B2, PAFAH1B3 MAOB 412/4885ADORA3 1371/4885AR 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.